source
- MapLight's schizophrenia drug fails primary endpoint in Phase 2, sending stock down over 60%MapLight Therapeutics saw its shares tumble more than 60% after a mid‑stage trial showed that its once‑daily schizophrenia candidate did not meet the primary efficacy endpoint, even though the over…
- CHMP recommends Minoryx’s ALD drug, rejects Zevra’s MeplyffaMinoryx Therapeutics finally scored backing from EU regulators for its neurological drug that’s faced multiple hurdles. Meanwhile, Zevra’s rare disease drug got a setback in Europe almost two years…Endpoints · 8d ago↗ source